This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tralokinumab

AstraZeneca PLC

Drug Names(s): CAT-354

Description: CAT-354 is a human anti-IL13 monoclonal antibody. IL-13 is an interleukin which has potent immunomodulatory effects. It is primarily secreted by TH2 lymphocytes.

Deal Structure: CAT-354 was developed by Cambridge Antibody Technology (CAT). In June 2006, CAT became a subsidiary of AstraZeneca.

AstraZeneca and LEO
In July 2016, AstraZeneca has entered into an agreement with LEO Pharma. Under the terms of the agreement, LEO Pharma will make an upfront payment to AstraZeneca of $115 million for the exclusive, global rights to tralokinumab in atopic dermatitis and any future additional dermatology indications. LEO Pharma will also pay AstraZeneca up to $1 billion in commercially-related milestones and up to mid-teen tiered percentage royalties on Product Sales. AstraZeneca will manufacture and supply tralokinumab to LEO Pharma. AstraZeneca will retain all rights to tralokinumab in respiratory disease and any other indications outside of dermatology.

In August 2016, AstraZeneca announced that it has completed the licensing agreement with LEO Pharma for the global licence to tralokinumab in skin diseases. Upon completion of the agreement,...See full deal structure in Biomedtracker

Partners: LEO Pharma A/S


Tralokinumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug